AIMT Aimmune Therapeutics to present data on AR101 at AAAAI Annual Meeting

When:
February 22, 2019 – February 25, 2019 all-day
2019-02-22T00:00:00-05:00
2019-02-26T00:00:00-05:00

$AIMT Aimmune Therapeutics to present data on AR101 at AAAAI Annual Meeting.

In a press release AIMT said that it will “present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San Francisco.”

Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting

Interestingly enough on the same date $AIMT also entered into a $170M loan agreement to fund AR101 commercialization.

Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement

$AIMT had released that they had submitted a BLA to the FDA for AR101 on December 21, 2018, which get FDA approval at anytime.

Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17

What is your Opinion?